Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that
Sophomore Zain Bravo, 19, sat in a dingy hotel a few weeks before the start of school. The drive from his hometown of Taft, California, to the University of Montana
BOSTON, Mass., Oct. 4, 2022 /PRNewswire/ Today the Amyloidosis Research Consortium (ARC), a patient-led research organization for amyloidosis diseases, announces the launch of ASPIRE: Amyloidosis
The AL amyloidosis market is expected to show positive growth owing to the factors such as increased incidence and the anticipated launch of novel therapies during the forecast period (2019-2032). LAS
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Tuesday that the European Commission has granted marketing authorization for AMVUTTRA